4 biologic agents on hot market competition
Published: 2011-07-12 06:59:00
Updated: 2011-07-12 06:59:00
The domestic biological drugs market so far enjoyed by three companies - Abbott/Eisai's Humira, Johnson & Johnson’s Remicade (infliximab), Wyeth’s Enbrel (etarnercept) - may be encountered with a fierce competition when Bristol-Myers Squibb's Orencia (abatacept) jumps in.
Orencia, the second-l...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.